Descriptive statistics (lower, median and upper quartile) at baseline by dichotomised entry diagnosis GPA, MPA and EGPA and by cluster affiliation
| All (N=195) | GPA (n=94) | MPA (n=90) | EGPA (n=11) | p Value diagnoses | Non-renal (n=48) | Renal with PR3 (n=61) | Renal without PR3 (n=65) | Cardiovascular (n=9) | Gastrointestinal (n=12) | p Value clusters | |
| Sex | 0.075 | 0.017 | |||||||||
| Male | 50% (97) | 54% (51) | 49% (44) | 18% (2) | 15 (31%) | 39 (64%) | 31 (48%) | 5 (56%) | 7 (58%) | ||
| Female | 50% (98) | 46% (43) | 51% (46) | 82% (9) | 33 (69%) | 22 (36%) | 34 (52%) | 4 (44%) | 5 (42%) | ||
| Age (years) | 55/69/ 77 | 50/64/74 | 59/71/81 | 50/64/74 | 0.002 | 49/61/70 | 54/65/74 | 60/73/81 | 61/76/79 | 55/79/84 | <0.001 |
| Age quartiles (years) | 0.016 | 0.004 | |||||||||
| 0–55 | 25% (49) | 32% (30) | 18% (16) | 27% (3) | 17 (35%) | 17 (28%) | 11 (17%) | 1 (11%) | 3 (25%) | ||
| 55–70 | 29% (57) | 30% (28) | 26% (23) | 55% (6) | 19 (40%) | 20 (33%) | 14 (22%) | 2 (22%) | 2 (17%) | ||
| 70–80 | 27% (53) | 27% (25) | 29% (26) | 18% (2) | 10 (21%) | 16 (26%) | 22 (34%) | 4 (44%) | 1 (8%) | ||
| 80–100 | 18% (36) | 12% (11) | 28% (25) | 0% (0) | 2 (4%) | 8 (13%) | 18 (28%) | 2 (22%) | 6 (50%) | ||
| P-Creatinine (µmol/L) | 75/152/ 319 | 66/93/192 | 156/267/464 | 50/57/63 | <0.001 | 54/65/77 | 110/213/324 | 138/259/402 | 85/99/326 | 187/282/508 | <0.001 |
| eGFR (mL/min) | 15/40/ 80 | 30/66/96 | 10/19/39 | 85/92/131 | <0.001 | 75/91/107 | 14/30/60 | 12/21/41 | 12/54/87 | 8/20/32 | <0.001 |
| CKD stages | <0.001 | <0.001 | |||||||||
| CKD 1–2 | 38% (74) | 59% (55) | 10% (9) | 91% (10) | 44 (92%) | 16 (26%) | 8 (12%) | 4 (44%) | 2 (17%) | ||
| CKD 3 | 19% (38) | 17% (16) | 23% (21) | 9% (1) | 4 (8%) | 15 (25%) | 17 (26%) | 1 (11%) | 1 (8%) | ||
| CKD 4 | 18% (36) | 13% (12) | 27% (24) | 0% (0) | 0 (0%) | 14 (23%) | 17 (26%) | 1 (11%) | 4 (33%) | ||
| CKD 5 | 24% (47) | 12% (11) | 40% (36) | 0% (0) | 0 (0%) | 16 (26%) | 23 (35%) | 3 (33%) | 5 (42%) | ||
| B-Haemoglobin (g/L) | 96/110/ 123 | 102/113/129 | 92/102/114 | 122/126/137 | <0.001 | 113/122/133 | 96/105/121 | 90/103/115 | 96/117/129 | 97/102/119 | <0.001 |
| Platelets (109/L) | 283/366/ 450 | 321/387/503 | 261/327/383 | 263/377/462 | <0.001 | 331/380/506 | 320/380/431 | 261/306/377 | 272/338/469 | 288/386/464 | 0.002 |
| CRP (mg/L) | 22/87/ 142 | 49/100/166 | 15/66/130 | 4/14/30 | <0.001 | 15/44/117 | 89/117/186 | 10/33/103 | 82/125/155 | 68/116/162 | <0.001 |
| ANCA | <0.001 | <0.001 | |||||||||
| PR3 | 51% (100) | 81% (76) | 27% (24) | 0% (0) | 31 (65%) | 61 (100%) | 0 (0%) | 3 (33%) | 5 (42%) | ||
| MPO | 43% (84) | 17% (16) | 71% (64) | 36% (4) | 11 (23%) | 0 (0%) | 64 (98%) | 3 (33%) | 6 (50%) | ||
| Negative | 6% (11) | 2% (2) | 2% (2) | 64% (7) | 6 (12%) | 0 (0%) | 1 (2%) | 3 (33%) | 1 (8%) | ||
| Cluster | <0.001 | ||||||||||
| A Non-renal | 25% (48) | 41% (39) | 1% (1) | 73% (8) | |||||||
| B Renal with PR3 | 31% (61) | 44% (41) | 22% (20) | 0% (0) | |||||||
| C Renal without PR3 | 33% (65) | 9% (8) | 62% (56) | 9% (1) | |||||||
| D Cardiovascular | 5% (9) | 3% (3) | 4% (4) | 18% (2) | |||||||
| E Gastrointestinal | 6% (12) | 3% (3) | 10% (9) | 0% (0) | |||||||
| Diagnosis | <0.001 | ||||||||||
| GPA | 48% (94) | 39 (81%) | 41 (67%) | 8 (12%) | 3 (33%) | 3 (25%) | |||||
| MPA | 46% (90) | 1 (2%) | 20 (33%) | 56 (86%) | 4 (44%) | 9 (75%) | |||||
| EGPA | 6% (11) | 8 (17%) | 0 (0%) | 1 (2%) | 2 (22%) | 0 (0%) |
ANCA, antineutrophil cytoplasmatic antibodies; CKD, chronic kidney disease; CRP, C reactive protein; CV, cardiovascular; eGFR, estimated glomerular filtration rate; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic granulomatosis; MPO, myeloperoxidase; n, observations; PR3, proteinase 3.